Mostrar el registro sencillo del ítem

dc.contributor.authorToribio-Fernandez, Raquel 
dc.contributor.authorHerrero-Fernandez, Beatriz 
dc.contributor.authorZorita, Virginia 
dc.contributor.authorLopez, Juan Antonio 
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorCriado, Gabriel
dc.contributor.authorPablos, Jose L
dc.contributor.authorCollas, Philippe
dc.contributor.authorSanchez-Madrid, Francisco 
dc.contributor.authorAndres, Vicente 
dc.contributor.authorGonzalez-Granado, Jose Maria 
dc.date.accessioned2020-01-14T11:10:49Z
dc.date.available2020-01-14T11:10:49Z
dc.date.issued2019-12
dc.identifier.citationJ Pathol. 2019; 249(4):509-22es_ES
dc.identifier.issn0022-3417es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8879
dc.description.abstractThe mechanisms by which lamin A/C in CD4+ T-cells control intestinal homeostasis and can cause inflammatory bowel disease (IBD) are unknown. Here, we explore lamin A/C in a mouse model of IBD. Adoptive transfer to Rag1-/- mice of Lmna-/- CD4+ T-cells, which have enhanced regulatory T-cells (Treg) differentiation and function, induced less severe IBD than wild-type T-cells. Lamin A/C deficiency in CD4+ T-cells enhanced transcription of the Treg master regulator FOXP3, thus promoting Treg differentiation, and reduced Th1 polarization, due to epigenetic changes in the Th1 master regulator T-bet. In mesenteric lymph nodes, retinoic acid (RA) released by CD103+ dendritic cells downregulated lamin A/C in CD4+ T-cells, enhancing Treg differentiation. However, non-RA-producing CD103- dendritic cells predominated in peripheral lymph nodes, facilitating lamin A/C expression in CD4+ T-cells and therefore Th1 differentiation. Our findings establish lamin A/C as a key regulator of Th differentiation in physiological conditions and show it as a potential immune-regulatory target in IBD. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.es_ES
dc.description.sponsorshipThis study was supported by grants to PC from the Research Council of Norway, to JMG-G from ISCIII (PI14/00526; PI17/01395; CP11/00145; CPII16/00022; EuroCellNet COST Action CA15214), the Miguel Servet Program and Fundación Ramón Aréces; to VA (RD12/0042/0028 SAF2013-46663-R, SAF2016-79490-R); to FS-M (SAF2017-82886-R; ERC-2011-AdG 294340-GENTRIS, CIBER CARDIOVASCULAR, PIE 13.0004-BIOIMID and CAM-B2017/BMD-3671-INFLAMUNE), to GC and JLP (PI16/00032 and RETICs RD16/0012 RIER), and to JV (BIO2015-67580-P; PRB3, IPT17/0019 - ISCIII-SGEFI/ERDF, ProteoRed) with co-funding from the European Regional Development Fund (ERDF) “Una manera de hacer Europa”. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). RTF is supported by the Fundación Ramón Aréces, VZG by ISCIII, BHF by the Instituto de Investigación Hospital 12 de Octubre (i+12), and JMG-G by the ISCIII Miguel Servet Program, i+12 and Universidad Autónoma de Madrid (UAM).es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionAMes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCD4+ T-cellses_ES
dc.subjectFOXP3es_ES
dc.subjectInflammatory bowel diseasees_ES
dc.subjectLamin A/Ces_ES
dc.subjectRegulatory T-celles_ES
dc.titleLamin A/C deficiency in CD4+ T-cells enhances regulatory T-cells and prevents inflammatory bowel diseasees_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID31372995es_ES
dc.format.volume249es_ES
dc.format.number4es_ES
dc.format.page509-522es_ES
dc.identifier.doi10.1002/path.5332es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderThe Research Council of Norway 
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) 
dc.contributor.funderUnión Europea. European Cooperation in Science and Technology (COST) 
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España) 
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.contributor.funderFundación ProCNIC 
dc.contributor.funderFundación Ramón Areces 
dc.contributor.funderAutonomous University of Madrid (España) 
dc.contributor.funderResearch Institute Hospital 12 de Octubre 
dc.description.peerreviewedes_ES
dc.embargo.terms2020-12-01es_ES
dc.identifier.e-issn1096-9896es_ES
dc.identifier.journalThe Journal of pathologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Fisiopatología Cardiovascular Molecular y Genéticaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Comunicación Intercelular en la Respuesta Inflamatoriaes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómicaes_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/294340es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional